Latest TroVax Stories
Studies show superiority of AE37 among peptide cancer vaccines WORCESTER, Mass. and TORONTO, May 22, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced three presentations demonstrating the superiority of the AE37 breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The presentations will be made at the annual meeting of the American Society of Clinical Oncology (ASCO)...
Up To 30 European Sites To Join 46 Active Sites In The US BETHESDA, Md., May 16, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®)-L personalized immune therapies for solid tumor cancers, today announced that its Phase III clinical trial with DCVax(®)-L for brain cancer has been initiated at King's College Hospital in the UK. (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO) This is one of the first...
TUBINGEN, Germany, March 27, 2013 /PRNewswire/ -- CureVac GmbH, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has initiated a double-blind, randomized Phase 2b clinical trial of its RNActive(®) cancer vaccine, CV9104, for the treatment of patients with castration-resistant prostate cancer. The Phase 2b trial will enroll up to 200 patients in eight European...
RARITAN, N.J., Dec. 27, 2012 /PRNewswire/ -- Veridex, LLC today announced that new Category I Current Procedural Technology (CPT) codes for circulating tumor cell (CTC) testing will go into effect in the United States on January 1, 2013. CPT codes are assigned by the American Medical Association (AMA) to medical, surgical, and diagnostic services to communicate uniform information about medical services and procedures among physicians, patients, payers and others for...
WORCESTER, Mass. and TORONTO, Nov. 13, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) today provided the following update on company initiatives. Antigen Express, Inc. (www.antigenexpress.com), a wholly-owned subsidiary of Generex, is in late Phase II clinical development of a novel immunotherapeutic for breast cancer (AE37) that demonstrates promising trends in preventing relapse. The interim results of the large, controlled, randomized, and single blinded trial...
TUEBINGEN, Germany, November 8, 2012 /PRNewswire/ -- immatics biotechnologies GmbH, a biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer, announced today that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma (RCC). The trial has completed patient inclusion and it is expected that around 345 patients will be randomized across 10...
BETHESDA, Md., Nov. 6 , 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio) a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it has initiated a collaboration with Sarah Cannon Research UK and the Leaders in Oncology Care (LOC) on a Phase I/II trial with DCVax(®)-Direct for metastatic colon cancer. Sarah Cannon Research UK is the UK arm of the Sarah Cannon Research Institute, which specializes in cancer drug...
BOTHELL, Wash., and VANCOUVER, British Columbia, Aug. 7, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it has initiated patient enrollment in its second Phase 3 clinical trial evaluating custirsen in patients with advanced prostate cancer. The AFFINITY trial will evaluate if custirsen when combined with second-line chemotherapy has the potential to improve survival outcomes for prostate cancer patients compared to second-line chemotherapy...
TUEBINGEN, Germany, July 29, 2012 /PRNewswire/ -- Paper highlights clinical and immunological activity of IMA901 in renal cell carcinoma (RCC) IMA901 is currently being evaluated in a pivotal phase 3 randomized study in patients with RCC immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of...
WORCESTER, Mass. and TORONTO, June 20, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) announced today the results of the Company's annual meeting of stockholders held on June 19, 2012. At the annual meeting of stockholders, the following directors were elected to serve on the Board of Directors until the next annual meeting of stockholders: John Barratt, Brian McGee, Nola Masterson, Mark Fletcher, Dr. James H. Anderson, Jr., MD, and Dr. Eric Von Hofe,...
